News|Articles|July 2, 2018

In the Lab eNewsletter

  • Pharmaceutical Technology\'s In the Lab eNewsletter-07-03-2018
  • Volume 13
  • Issue 7

Shimadzu’s New Q-TOF System Enhances Mass Spectrometry

The company’s new LCMS-9030 system is designed for high resolution and accurate mass detection.

Shimadzu’s new quadrupole time-of-flight (Q-TOF) LCMS-9030 system, a research-grade mass spectrometer, is designed to deliver-high resolution, accurate-mass detection with fast data acquisition rates. The new tool allows scientists to identify and quantify more compounds with greater confidence, according to the company.

The system utilizes the same engineering DNA from the company’s high-performance triple quadrupole (LC-MS/MS) platform, which is integrated with TOF architecture to achieve high-mass accuracy workflows with high-sensitivity, high-speed, and high-resolution detection.

The company unveiled its LCMS-9030 system at the 66th Annual American Society for Mass Spectrometry (ASMS) Conference on mass spectrometry and allied topics on June 3–7 in San Diego, CA.

Key technology drivers

Ultra-fast (UF) acquisition rates and core ion beam technologies developed for the triple quadrupole platform have created new possibilities in quantitative mass spectrometry by delivering high sensitivity, specific quantitation, and enhanced target compound verification, as stated by the company.

The new LCMS-9030 Q-TOF builds on this platform by rethinking time-of-flight detection. In the LCMS-9030, core ion beam technologies approach ion gating using UFaccumulation to create a precise pulse of ions into the flight tube, which has been optimized for high sensitivity and high resolution using iRefTOF reflectron technology. The iRefTOF generates a reflectron field, which delivers a high resolution for the flight path with highly stable mass accuracy, according to the company.

“Our Q-TOF technology on the LCMS-9030 will push the boundaries further for high mass accuracy and high mass resolution detection, and will make an impact across all applications, from small-molecule quantitation to complex intact protein analysis. This technology highlights Shimadzu’s passion for making something new and innovative as well as our commitment to making analysis better and promoting better science,” said Shuzo Maruyama, general manager, Analytical and Measuring Instruments Division, Shimadzu, in a company press release.

Source: Shimadzu


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.